Chromosomes, 11Q and cancer: A review

Journal of Pathology

Volumn 187, Issue 1, 1999, Pages 28-38

  Koreth, John ^a   Bakkenist, Christopher J ^a   McGee, James O'D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer; Chromosome 11q; Cytogenetics; Recombination; Review

Indexed keywords

CANCER; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; DNA RECOMBINATION; DNA REPAIR; GENE AMPLIFICATION; GENE CONVERSION; GENE LOCUS; PRIORITY JOURNAL; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; HUMANS; MUTATION; RECOMBINATION, GENETIC;

EID: 0032962587     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R     Document Type: Review

References (126)

1. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997; 386: 761-763.
2. Prado F, Aguilera A. Role of reciprocal exchange, one-ended invasion crossover and single-strand annealing on inverted and direct repeat recombination in yeast: different requirements for the RAD1, RAD10, and RAD52 genes. Genetics 1995; 139: 109-123.
3. Holliday R. A mechanism for gene conversion in fungi. Genet Res Cam 1964; 5: 282-304.
4. Meselson MS, Radding CM. A general model for genetic recombination. Proc Natl Acad Sci USA 1975; 72: 358-361.
5. Szostak JW, Orr WT, Rothstein RJ, Stahl FW. The double-strand-break repair model for recombination. Cell 1983; 33: 25-35.
6. Klein HL. Different types of recombination events are controlled by the RAD1 and RAD52 genes of Saccharomyces cerevisiae. Genetics 1988; 120: 367-377.
7. Yunis J. Chromosomal rearrangements, gene, and fragile sites in cancer: clinical and biologic implications. In: De Vita Jr VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: J. B. Lippincott, 1986; 93-128.
8. Haluska FG, Tsujimoto Y, Groce CM. Oncogene amplification by chromosome translocation in human malignancy. Annu Rev Genet 1987; 21: 321-347.
9. Meuth M. The structure of mutation in mammalian cells. Biochim Biophys Acta 1990; 1032: 1-17.
10. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-149.
11. Knudson AJ. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
12. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779-784.
13. Scrable HJ, Sapienza C, Cavenee WK. Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression. Adv Cancer Res 1990; 54: 25-62.
14. Collins FS, Weissman SM. The molecular genetics of human hemoglobin. Prog Nucleic Acid Res Mol Biol 1984; 31: 315-462.
15. Phear G, Armstrong W, Meuth M. Molecular basis of spontaneous mutation of the aprt locus of hamster cells. J Mol Biol 1989; 209: 577-582.
16. Strand M, Prolla TA, Liskay RM, Petes TD. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair [see comments] [published erratum appears in Nature 1994; Apr 7; 368(6471): 569]. Nature 1993; 365: 274-276.
17. Henderson ST, Petes TD. Instability of simple sequence DNA in Saccharomyces cerevisiae. Mol Cell Biol 1992; 12: 2749-2757.
18. de BJ, Ripley LS. Demonstration of the production of frameshift and base-substitution mutations by quasipalindromic DNA sequences. Proc Natl Acad Sci USA 1984; 81: 5528-5531.
19. Meyn MS. High spontaneous intrachromosonial recombination rates in ataxia-telangiectasia. Science 1993; 260: 1327-1330.
20. Thibodeau SN, Bren G, Schaid D. Microsatellile instability in cancer of the proximal colon [see comments]. Science 1993; 260: 816-819.
21. Lehrman MA, Russell DW, Goldslein JL, Brown MS. Alu-Alu recombination deletes splice acceptor sites and produces secreted low density lipoprotein receptor in a subject with familial hypercholesterolemia. J Biol Chem 1987; 262: 3354-3361.
22. Nicholls RD, Fischel GN, Higgs DR. Recombination at the human alpha-globin gene cluster: sequence features and topological constraints Cell 1987; 49: 369-378.
23. Vanin EF, Henthorn PS, Kioussis D, Grosveld F, Smithies O. Unexpected relationships between four large deletions in the human beta-globin gene cluster. Cell 1983; 35: 701-709.
24. Nalbantoglu J, Hartley D, Phear G, Tear G, Meuth M. Spontaneous deletion formation at the aprt locus of hamster cells: the presence of short sequence homologies and dyad symmetries at deletion termini. EMBO J 1986; 5: 1199-1204.
25. Mager DL, Henthorn PS, Smithies O. A Chinese G gamma + (A gamma delta beta)zero thalassemia deletion: comparison to other deletions in the human beta-globin gene cluster and sequence analysis of the breakpoints. Nucleic Acids Res 1985; 13: 6559-6575.
26. Klein HL. Lack of association between intrachromosomal gene conversion and reciprocal exchange. Nature 1984; 310: 748-753.
27. Aguilera A, Klein HL. Yeast intrachromosomal recombination: long gene conversion tracts are preferentially associated with reciprocal exchange and require the RAD1 and RAD3 gene products. Genetics 1989; 123: 683-694.
28. Dornfeld KJ, Livingston DM. Plasmid recombination in a rad52 mutant of Saccharomyces cerevisiae. Genetics 1992; 131: 261-276.
29. Yuan LW, Keil RL. Distance-independence of mitotic intrachromosomal recombination in Saccharomyces cerevisiae. Genetics 1990; 124: 263-273.
30. Baltimore D. Gene conversion: some implications for immunoglobulin genes. Cell 1981; 24: 592-594.
31. Esposito MS. Evidence that spontaneous mitotic recombination occurs at the two-strand stage. Proc Natl Acad Sci USA 1978; 75: 4436-4440.
32. Alitalo K. Schwab M. Oncogene amplification in human cells. Adr Cancer Res 1986; 47: 235-282.
33. Toledo F, Le RD, Buttin G, Debatisse M. Co-amplified markers alternate in megabase long chromosomal inverted repeats and cluster independently in interphase nuclei at early steps of mammalian gene amplification. EMBO J 1992; 11: 2665-2673.
34. Jeffreys AJ, Brookfield JE, Semeonoff R. Positive identification of an immigration test-case using human DNA fingerprints. Nature 1985; 317: 818-819.
35. McClintock B. Chromosomal organisation and genetic expression. Cold Spring Harbor Symp Quant Biol 1951; 16: 13-47.
36. Coquelle A, Pipiras F., Toledo F, Buttin G, Debatisse M. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and set boundaries to early amplicons. Cell 1997; 89: 215-225.
37. James MR, Richard C3, Schott JJ, et al. A radiation hybrid map of 506 STS markers spanning human chromosome 11. Nature Genet 1994; 8: 70-76.
38. Shows TB, Alders M, Bennett S, et al. Report of the Fifth International Workshop on Human Chromosome 11 Mapping 1996. Cytogenet Cell Genet 1996; 74: 1-56.
39. Cox DR, Green ED, Lander ES, Cohen D, Myers RM. Assessing mapping progress in the Human Genome Project. Science 1994; 265: 2031-2032.
40. Litt M, Kramer P, Kort E, et al. The CEPH consortium linkage map of human chromosome 11. Genomics 1995; 27: 101-112.
41. Qin S, Nowak NJ, Zhang J, et al. A high-resolution physical map of human chromosome 11. Proc Natl Acad Sci USA 1996; 93: 3149-3154.
42. Perlin MW, Duggan DJ, Davis K, et al. Rapid construction of integrated maps using inner product mapping: YAC coverage of human chromosome 11. Genomics 1995; 28: 315-327.
43. van HV, Little PF. Report of the Fourth International Workshop on Human Chromosome 11 Mapping 1994. Cytogenetic Cell Genet 1995; 69: 127-158.
44. Fain PR, Kort EN, Yousry C, James MR, Litt M. A high resolution CEPH crossover mapping panel and integrated map of chromosome 11. Hum Mol Genet 1996; 5: 1631-1636.
45. Saccone S, De SA, Della VG, Bernardi G. The highest gene concentrations in the human genome are in lelomeric bands of metaphase chromosomes. Proc Natl Acad Sci USA 1992; 89: 4913-4917.
46. Mitelman F, Kaneko Y, Trent JM. Report of the committee on chromosome changes in neoplasia. Cytogenet Cell Genet 1990: 55: 358-386.
47. Tsujimoto Y, Yunis J, Onorato SL, Erikson J, Nowell PC, Croce CM, Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11:14) chromosome translocation. Science 1984; 224: 1403-1406.
48. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991; 88: 9638-9642.
49. Brookes S, Lammie GA, Schuuring E, Dickson C, Peters G. Linkage map of a region of human chromosome band 11q13 amplified in breast and squamous cell tumors. Genes Chromosomes Cancer 1992; 4: 290-301.
50. Adelaide J, Monges G, Derderian C, Seitz JF, Birnbaum D. Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer 1995; 71: 64-68.
51. Jiang W, Zhang YJ, Kahn SM, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993; 90: 9026-9030.
52. Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993; 196: 1010-1016.
53. Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995; 14: 227-251.
54. Represa J, Leon Y, Miner C, Giraldez F. The int-2 proto-oncogene is responsible for induction of the inner ear. Nature 1991; 353: 561-563.
55. Bonne TB, Korostishevsky M, Kalinsky H, et al. Genetic mapping of the gene for Usher syndrome: linkage analysis in a large Samaritan kindred. Genomics 1994; 20: 36-42.
56. Wu H, Parsons JT. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 1993; 120: 1417-1426.
57. Okamura H, Resh MD. p80/85 cortactin associates with the Src SH2 domain and colocalizes with v-Src in transformed cells. J Biol Chem 1995; 270: 26 613-26 618.
58. van DH, Brok H, Schuuring SE, Schuuring E. The redistribution of cortactin into cell-matrix contact sites in human carcinoma cells with 11q13 amplification is associated with both overexpression and post-translational modification. J Biol Chem 1997; 272: 7374-7380.
59. Patel AM, Incognito LS, Schechter GL, Wasilenko WJ, Somers KD. Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene 1996; 12: 31-35.
60. Karlseder J, Zeillinger R, Schneeberger C, et al. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer 1994; 9: 42-48.
61. Thakker RV, Bouloux P, Wooding C, et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 1989; 321: 218-224.
62. Bale SJ, Bale AE, Stewart K, et al. Linkage analysis of multiple endocrine neoplasia type 1 with INT2 and other markers on chromosome 11 [published erratum appears in Genomics 1989; 5: 166]. Genomics 1989; 4: 320-322.
63. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-407.
64. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nature Genet 1997; 16: 375-378.
65. Mariman EC, van BS, Cremers CW, van BF, Ropers HH. Analysis of a second family with hereditary non-chromaffin paragangliomas locates the underlying gene at the proximal region of chromosome 11q. Hum Genet 1993; 91: 357-361.
66. Chuaqui RF, Zhuang Z, Emmert BM, Liotta LA, Merino MJ. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 1997; 150: 297-303.
67. Nayar R, Zhuang Z, Merino MJ, Silverberg SG. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum Pathol 1997; 28: 277-282.
68. Zhuang Z, Merino MJ, Chuaqui R, Liotta LA, Emmart BM. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res 1995; 55: 467-471.
69. Gu Y, Nakamura T, Alder H, et al. The t(4:11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71: 701-708.
70. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691-700.
71. Nakamura T, Alder H, Gu Y, et al. Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci USA 1993; 90: 4631-4635.
72. Baffa R, Negrini M, Schichman SA, Huebner K, Croce CM. Involvement of the ALL-1 gene in a solid tumor. Proc Natl Acad Sci USA 1995; 92: 4922-4926.
73. Lindblom A, Sandelin K, Iselius L, et al. Predisposition for breat cancer in carriers of constitutional translocalion 11q;22q. Am J Hum Genet 1994; 54: 871-876.
74. Meerabux JM, Cotter FE, Kearney L, et al. Molecular cloning of a novel 11q23 breakpoint associated with non-Hodgkin's lymphoma. Oncogene 1994; 9: 893-898.
75. Heutink p, Van dMA, Sandkuijl LA, et al. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum Mol Genet 1992; 1: 7-10.
76. Swift M, Morrell D, Mussey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia [see comments]. N Engl J Med 1991; 325: 1831-1836.
77. Wooster R, Ford D, Mangion J, et al. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. Hum Genet 1993; 92: 91-94.
78. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995; 4: 2025-2032.
79. Uziel T, Savitsky K, Platzer M, et al. Genomic organization of the ATM gene. Genomics 1996; 33: 317-320.
80. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995; 4: 2025-2032.
81. Lavin MF, Khanna KK, Beamish H, Spring K, Walters D, Shiloh Y. Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase. Trends Biochim Sci 1995; 20: 382-383.
82. Kastan MB, Zhan Q, el DW, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
83. Kirsch IR. V(D)J recombination and ataxia-telangiectasia: a review. Int J Radiat Biol 1994; 66: S97-S108.
84. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996; 92: 130-134.
85. Vorechovsky I, Rasio D, Luo L, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 1996; 56: 2726-2732.
86. FitzGerald MG, Bean JM, Hedge SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer [see comments]. Nature Genet 1997; 15: 307-310.
87. Blacker H, Rasheed BK, McLendon RE, et al. Microsatellile analysis of childhood brain tumors. Genes Chromosomes Cancer 1996; 15: 54-63.
88. Baffa R, Negrini M, Mandes B, et al. Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach. Cancer Res 1996; 56: 268-272.
89. Bethwaite PB, Koreth J, Herrington CS, McGee JO. Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. Br J Cancer 1995; 71: 814-818.
90. Carter SL, Negrini M, Baffa R, et al. Loss of heterozygosity at 11q22 q23 in breast cancer. Cancer Res 1994; 54: 6270-6274.
91. Dahiya R, McCarville J, Lee C, et al. Chromosomes 3p24-25, 3p22 12 and 11p15, p12, q22, q23 24 loci deletion in human prostate cancer. Proc Am Assoc Cancer Res 1997; 00: 427.
92. Davis M, Hitchcock A, Foulkes WD, Campbell IG. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996; 56: 741-744.
93. Foulkes WD, Campbell IG, Stamp GW, Trowsdale J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer 1993; 67: 268-273.
94. Gabra H, Taylor L, Cohen BB, et al. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer 1995; 72: 367-375.
95. Gabra H, Watson JE, Taylor KJ, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3 q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996; 56: 950-954.
96. Hampton GM, Penny LA, Baergen RN, et al. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci USA 1994; 91: 6953-6957.
97. Hampton GM, Mannermaa A, Winquist R, et al. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3 Cancer Res 1994; 54: 4586-4589.
98. Herbst RA, Larson A, Weiss J, Cavanee WK, Hampton GM, Arden KC. A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Cancer Res 1995; 55: 2494-2496.
99. Hui AB, Lo KW, Leung SF, et al. Loss of heterozygosity on the long arm of chromosome 11 in nasopharyngeal carcinoma. Cancer Res 1996; 56: 3225-3229.
100. Iizuka M, Sugiyama Y, Shiraishi M, Jones C, Sekiya T. Allelic losses in human chromosome 11 in lung cancers. Genes Chromosomes Cancer 1995; 13: 40-46.
101. Keldysh PL, Dragani TA, Fleischman EW, et al. 11q deletions in human colorectal carcinomas: cytogenetics and restriction fragment length polymorphism analysis. Genes Chromosomes Cancer 1993; 6: 45-50.
102. Koreth J, Bethwaite PB, McGee JO. Mutation at chromosome 11q23 in human non-familial breast cancer: a microdissection microsatellite analysis. J Pathol 1995; 176: 11-18.
103. Koreth J, Bakkenist CJ, McGee JO. Allelic deletions at chromosome 11q22 q23.1 and 11q25-qterm are frequent in sporadic breast but not colorectal cancers. Oncogene 1997; 14: 431-437.
104. Negrini M, Rasio D, Hampton GM, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res 1995; 55: 3003-3007.
105. Rasio D, Negrini M, Manenti G, Dragani TA, Croce CM. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res 1995; 55: 3988-3991.
106. Shaw ME, Knowles MA. Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes Cancer 1995; 13: 1-8.
107. Tomlinson IP, Bodmer WF. Chromosome 11q in sporadic colorectal carcinoma: patterns of allele loss and their significance for tumorigenesis. J Clin Pathol 1996; 49: 386-390.
108. Uzawa K, Suzuki H, Komiya A, et al. Evidence for two distinct tumor-suppressor gene loci on the long arm of chromosome 11 in human oral cancer. Int J Cancer 1996; 67: 510-514.
109. Winqvist R, Hampton GM, Mannermaa A, et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 1995; 55: 2660-2664.
110. Gioeli D, Conway K, Weissman BE. Localization and characterization of a chromosome 11 tumor suppressor gene using organotypic raft cultures. Cancer Res 1997; 57: 1157-1165.
111. Robertson G, Coleman A, Lugo TG. A malignant melanoma tumor suppressor on human chromosome 11. Cancer Res 1996; 56: 4487-4492.
112. Zenklusen JC, Oshimura M, Barrett JC, Conti CJ. Human chromosome 11 inhibits tumorigenicity of a murine squamous cell carcinoma cell line. Genes Chromosomes Cancer 1995; 13: 47-53.
113. Negrini M, Sabbioni S, Possati L, et al. Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11. Cancer Res 1994; 54: 1331-1336.
114. Srivatsan ES, Benedict WF, Stanbridge EJ. Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. Cancer Res 1986; 46: 6174-6179.
115. Phillips KK, Welch DR, Miele ME, Lee JH, Wei LL, Weissman BE. Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer Res 1996; 56: 1222-1227.
116. Horikawa I, Okamoto A, Yokota J, Oshimura M. Genetic heterogeneity of chromosome 11 associated with tumorigenicity in HeLa D98-OR cells. Cancer Genet Cytogenet 1995; 85: 97-100.
117. Turc CC, Philip I, Berger MP, Philip T, Lenoir GM. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24:q12). Cancer Genet Cytogenet 1984; 12: 1-19.
118. Hromas R, May W, Denny C, et al. Human FLI-1 localizes to chromosome 11Q24 and has an aberrant transcript in neuroepithelioma. Biochim Biophys 1993; 1172: 155-158.
119. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-165.
120. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11:22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993; 90: 5752-5756.
121. Diaz MO, Le BM, Pitha P, Rowley JD. Interferon and c-ets-1 genes in the translocation (9:11)(p22;q23) in human acute monocytic leukemia. Science 1986; 231: 265-267.
122. Rovigatti U, Watson DK, Yunis JJ. Amplification and rearrangement of Hu-ets-1 in leukemia and lymphoma with involvement of 11q23. Science 1986; 232: 398-400.
123. Goyns MH, Hann IM, Stewart J, Gegonne A, Birnie GD. The c-ets-1 proto-oncogene is rearranged in some cases of acute lymphoblastic leukaemia. Br J Cancer 1987: 56: 611-613.
124. Watson DK, McWilliams SM, Nunn MF, Duesberg PH, O'Brien SJ, Papas TS. The ets sequence from the transforming gene of avian erythroblastosis virus. E26, has unique domains on human chromosomes 11 and 21: both loci are transcriptionally active. Proc Natl Acad Sci USA 1985; 82: 7294-7298.
125. Fisher RJ, Koizumi S, Kondoh A, et al. Human ETS1 oncoprotein. Purification, isoforms, -SH modification, and DNA sequence-specific binding. J Biol Chem 1992; 267: 17 957- 17 965.
126. Gudmundsson J, Barkardottir RB, Eiriksdottir G, et al. Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br J Cancer 1995; 72: 696-701.